PF-06939999
oral SAM-competitive PRMT5 inhibitor Ph. I candidate for solid tumors (adv. or met.) SBDD utilizing PRMT5:MEP50 w/ A9145C Molecular Cancer Therapy Pfizer Oncology
Molecules of the Month - November 2021
Molecules of the Month
- paxlovid
- GS-621763
- ASP2453
- SY-5609
- BIIB091
- "compound Ia"
- DS96432529
- "compound 27"
- tepotinib
- PF-06939999
- "compound 5"
- compound 59
- M5717
- compound 1